As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance ...
The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback